| Name | Title | Contact Details |
|---|---|---|
Sean Iverson |
Vice President of Marketing and Communications | Profile |
Tugba ISIKER |
Associate Director of Financial Systems | Profile |
Ken Freedman |
Chief Revenue Officer (CRO) | Profile |
Andy Cook |
Director of People Analytics | Profile |
Manuela Valente |
Senior Vice President, Chief People Officer | Profile |
Day One Biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine.
EpicentRx is a patient-driven immuno-oncology company with minimally toxic therapies that work across diverse patient populations and tumor types for the best possible quality of life during treatment.
Synspira Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to significantly improving the lives of people with cystic fibrosis (CF) and other rare diseases.
Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead compounds, cabozantinib and cobimetinib, tells the story of our evolution as a company. Each of these compounds were discovered in our own laboratories and advanced by us into clinical development. In addition, we have leveraged our earlier stage drug discovery and development capabilities to establish multiple partnerships and collaborations with leading pharmaceutical and biopharmaceutical partners. These alliances are designed to advance the development of multiple Exelixis-discovered therapies, and allow Exelixis to focus on maximizing the potential of cabozantinib. Exelixis has worldwide rights to cabozantinib, which we believe could have the potential to treat a wide variety of cancers. Cabozantinib received its initial regulatory approval for a single indication in 2012, and is marketed for that indication under the trade name COMETRIQ®. Cabozantinib is also the subject of a broad, global clinical development program that includes approximately 45 ongoing or planned clinical trials. Exelixis is the sponsor of two active global, randomized phase 3 pivotal trials: the METEOR trial in metastatic renal cell carcinoma, for which positive top-line results were announced in July 2015, and the CELESTIAL trial in advanced hepatocellular carcinoma. Founded and incorporated in 1994, Exelixis is headquartered in South San Francisco, California. We are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer.
Learn how we’re changing the world of medicine. Discover career opportunities, our product pipeline, and browse media resources. Meet Moderna.